相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular profiling for precision cancer therapies
Eoghan R. Malone et al.
GENOME MEDICINE (2020)
Generating comparative evidence on new drugs and devices after approval
Andrea Cipriani et al.
LANCET (2020)
Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers A Systematic Review and Meta-analysis
Fausto Petrelli et al.
JAMA ONCOLOGY (2020)
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Alex H. Wagner et al.
NATURE GENETICS (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
D. L. van der Velden et al.
NATURE (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies
Suanna Steeby Bruinooge et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
The promise of ESCAT: a new system for evaluating cancer drug-target pairs
Bishal Gyawali et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Genenames.org: the HGNC and VGNC resources in 2019
Bryony Braschi et al.
NUCLEIC ACIDS RESEARCH (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Text-mining clinically relevant cancer biomarkers for curation into the CIViC database
Jake Lever et al.
GENOME MEDICINE (2019)
Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Katherine C. Kurnit et al.
CLINICAL CANCER RESEARCH (2018)
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
David Tamborero et al.
GENOME MEDICINE (2018)
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
John Marquart et al.
JAMA ONCOLOGY (2018)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.
Tanya Skamene et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers
Subotheni Thavaneswaran et al.
MEDICAL JOURNAL OF AUSTRALIA (2018)
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie
Clemence Basse et al.
ESMO OPEN (2018)
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Pam K. Mangat et al.
JCO PRECISION ONCOLOGY (2018)
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
Christian Rolfo et al.
ESMO OPEN (2018)
The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations
Linda Huang et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2017)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
Malachi Griffith et al.
NATURE GENETICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
eGARD: Extracting associations between genomic anomalies and drug responses from text
A. S. M. Ashique Mahmood et al.
PLOS ONE (2017)
Molecular Tumor Boards: current practice and future needs
D. L. van der Velden et al.
ANNALS OF ONCOLOGY (2017)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
Apostolia-Maria Tsimberidou et al.
JCO PRECISION ONCOLOGY (2017)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
HGVS Recommendations for the Description of Sequence Variants: 2016 Update
Johan T. den Dunnen et al.
HUMAN MUTATION (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome
Alexandria D. Taylor et al.
TRANSLATIONAL ONCOLOGY (2016)
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
Tracy L. Stockley et al.
GENOME MEDICINE (2016)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms AMeta-analysis
Maria Schwaederle et al.
JAMA ONCOLOGY (2016)
The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies
Sara E. Patterson et al.
HUMAN GENOMICS (2016)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Maria Schwaederle et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Funda Meric-Bernstam et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Funda Meric-Bernstam et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Prioritizing targets for precision cancer medicine
F. Andre et al.
ANNALS OF ONCOLOGY (2014)
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
Eliezer M. Van Allen et al.
NATURE MEDICINE (2014)
ClinVar: public archive of relationships among sequence variation and human phenotype
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2014)
Organizing knowledge to enable personalization of medicine in cancer
Benjamin M. Good et al.
GENOME BIOLOGY (2014)
Using computerised decision support to improve compliance of cancer multidisciplinary meetings with evidence-based guidance
Vivek Patkar et al.
BMJ OPEN (2012)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
分享论文
